654 related articles for article (PubMed ID: 27370205)
1. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
2. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
3. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
[TBL] [Abstract][Full Text] [Related]
4. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
5. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer.
Yang R; Zhao N; Liao A; Wang H; Qu A
Med Dosim; 2016; 41(3):236-41. PubMed ID: 27400663
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
8. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
[TBL] [Abstract][Full Text] [Related]
11. Modelling of organ-specific radiation-induced secondary cancer risks following particle therapy.
Stokkevåg CH; Fukahori M; Nomiya T; Matsufuji N; Engeseth GM; Hysing LB; Ytre-Hauge KS; Rørvik E; Szostak A; Muren LP
Radiother Oncol; 2016 Aug; 120(2):300-6. PubMed ID: 27424291
[TBL] [Abstract][Full Text] [Related]
12. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
14. Risk of radiation-induced secondary rectal and bladder cancer following radiotherapy of prostate cancer.
Stokkevåg CH; Engeseth GM; Hysing LB; Ytre-Hauge KS; Ekanger C; Muren LP
Acta Oncol; 2015; 54(9):1317-25. PubMed ID: 26230629
[TBL] [Abstract][Full Text] [Related]
15. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
[TBL] [Abstract][Full Text] [Related]
16. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.
Murray LJ; Thompson CM; Lilley J; Cosgrove V; Franks K; Sebag-Montefiore D; Henry AM
Phys Med Biol; 2015 Feb; 60(3):1237-57. PubMed ID: 25590229
[TBL] [Abstract][Full Text] [Related]
17. Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy.
Tward JD; Jarosek S; Chu H; Thorpe C; Shrieve DC; Elliott S
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1443-1453. PubMed ID: 27325475
[TBL] [Abstract][Full Text] [Related]
18. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Parry MG; Nossiter J; Sujenthiran A; Cowling TE; Patel RN; Morris M; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1219-1229. PubMed ID: 33279595
[TBL] [Abstract][Full Text] [Related]
19. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
